Rhythm Pharmaceuticals, Inc. (RYTM) key performance indicators and operating metrics (11 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Net Product Revenues from Global Sales of IMCIVREE (setmelanotide) | 60.1M | FY2026-Q1 |
| Product Revenue from IMCIVREE (Setmelanotide) in the United States | 36.9M | FY2026-Q1 |
| Product Revenue from IMCIVREE (Setmelanotide) outside the United States | 23.2M | FY2026-Q1 |
| United States Share of Fourth Quarter Net Product Revenues | 61.00 percent | FY2026-Q1 |
| IMCIVREE Outside the United States Revenue as Percent of Product Revenue | 39.00 percent | FY2026-Q1 |
| Sequential Net Product Revenue Growth for IMCIVREE | 5.00 percent | FY2026-Q1 |
| Research and Development Expenses (GAAP) | 41.7M | FY2026-Q1 |
| Selling, General and Administrative Expenses (GAAP) | 63.6M | FY2026-Q1 |
| Other income (expense), net | -500K | FY2025-Q4 |
| IMCIVREE Revenue Outside the United States | 13.2M | FY2025-Q1 |
| Cost of sales (COGS) | 3.65M | FY2025-Q1 |
Back to RYTM overview · RYTM earnings · RYTM holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.